Effect of Lingqi Huangban granule plus intravitreal ranibizumab on macular edema induced by retinal vein occlusion: a randomized controlled clinical trial.

Effect of Lingqi Huangban granule plus intravitreal ranibizumab on macular edema induced by retinal vein occlusion: a randomized controlled clinical trial. J Tradit Chin Med. 2020 Apr;40(2):305-310 Authors: Lu B, Wu X Abstract OBJECTIVE: To investigate the effect of Lingqi Huangban granule (LQHB) plus intravitreal ranibizumab in the treatment of macular edema (ME) induced by retinal vein occlusion (RVO). METHODS: A prospective, randomized controlled study was conducted. A total of 60 subjects with RVO induced ME were randomized into control group (CG) (30 eyes) and LQHB group (LQHBG) (30 eyes). CG patients underwent intravitreal ranibizumab (IVR) injections. LQHBG patients were treated with oral LQHB combined with IVR injections. In order to reduce the financial burden of the injections, we used one injection and pro re nata (PRN) regimen for both groups. The best-corrected visual acuity (BCVA), central macular thickness (CMT), and mean number of injections were evaluated at the beginning of treatment and 3, 6, 9 and 12 months afterward. All the subjects were followed up for 1 year. RESULTS: At the beginning of treatment, there were no statistically significant differences between the two groups in terms of the general condition of patients (P> 0.05). At 3, 6, 9 and 12 months after treatment, however, the BCVA scores improved and the CMT measurements decreased in all patients (P
Source: Journal of Traditional Chinese Medicine - Category: Complementary Medicine Authors: Tags: J Tradit Chin Med Source Type: research

Related Links:

Bayer's finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetesFinerenone significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care / Finerenone significantly reduced the combined key secondary endpoint of cardiovascular death or non-fatal cardiovascular events / Chronic kidney disease impacts 4 in 10 patients with type 2 diabetes and is a deadly condition that is underrecognized / Finerenone is the first investigational non-steroid...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
Publication date: Available online 9 July 2020Source: International Journal of Pediatrics and Adolescent MedicineAuthor(s): Rezkalla Akkary, Mirella Ripepi, orion Akokpe, Hamdi Louati, Clemence Klipfel, Stephan Geiss
Source: International Journal of Pediatrics and Adolescent Medicine - Category: Pediatrics Source Type: research
Publication date: Available online 8 July 2020Source: International Journal of Pediatrics and Adolescent MedicineAuthor(s): Halszka Kamińska, Anna Kostera-Pruszczyk, Anna Potulska-Chromik, Bożena Werner
Source: International Journal of Pediatrics and Adolescent Medicine - Category: Pediatrics Source Type: research
Publication date: Available online 8 July 2020Source: International Journal of Pediatrics and Adolescent MedicineAuthor(s): Amr Mousa, Amani Al-Kofide, Khawar Siddiqui, Hindi Alhindi, Nada Alshaikh, Essam Alshail
Source: International Journal of Pediatrics and Adolescent Medicine - Category: Pediatrics Source Type: research
Publication date: Available online 9 July 2020Source: Academic PediatricsAuthor(s): Darcy A. Thompson, Jeanne M. Tschann
Source: Academic Pediatrics - Category: Pediatrics Source Type: research
Publication date: Available online 9 July 2020Source: Academic PediatricsAuthor(s): Su-Ting T. Li, Melissa D. Klein, Dorene F. Balmer, Maryellen E. Gusic
Source: Academic Pediatrics - Category: Pediatrics Source Type: research
Publication date: Available online 8 July 2020Source: Academic PediatricsAuthor(s): Anne Martin, Anna D. Johnson, Sherri Castle
Source: Academic Pediatrics - Category: Pediatrics Source Type: research
Publication date: Available online 5 June 2020Source: Academic PediatricsAuthor(s): Sebastian Lara, Christopher W. Foster, Matthew Hawks, Michael Montgomery
Source: Academic Pediatrics - Category: Pediatrics Source Type: research
UC Davis Health is looking to consolidate its administrative services into a large building it will renovate in Rancho Cordova.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
The San Francisco digital health company launched a new app in May that allows physicians to securely video call patients, without requiring downloads or log-ins.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
More News: China Health | Clinical Trials | Complementary Medicine | Eyes | Lucentis | Ranibizumab Injection | Statistics | Study | Vitamin A